We are live on ! Find out more
DNLI icon

Denali Therapeutics

230 hedge funds and large institutions have $1.93B invested in Denali Therapeutics in 2025 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 84 increasing their positions, 64 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more call options, than puts

Call options by funds: $2.08M | Put options by funds: $630K

31% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 64

25% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 36

4% more funds holding

Funds holding: 222230 (+8)

1.11% more ownership

Funds ownership: 93.6%94.71% (+1.1%)

4% more capital invested

Capital invested by funds: $1.85B → $1.93B (+$76.1M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
230
Holders Change
+8
Holders Change %
+3.6%
% of All Funds
3.03%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
45
Increased
84
Reduced
64
Closed
36
Calls
$2.08M
Puts
$630K
Net Calls
+$1.45M
Net Calls Change
+$1.11M
Name Holding Trade Value Shares
Change
Change in
Stake
CGL
51
Clarius Group LLC
Washington
$5.16M
EP
52
Edgestream Partners
New Jersey
$4.8M +$4.83M +342,923 New
American Century Companies
53
American Century Companies
Missouri
$4.45M -$440K -31,227 -9%
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4.41M +$802K +56,970 +22%
PC
55
Pier Capital
Connecticut
$4.4M -$291K -20,708 -6%
Axa
56
Axa
France
$4.11M +$6.64K +472 +0.2%
Hudson Bay Capital Management
57
Hudson Bay Capital Management
Connecticut
$4.06M +$563K +40,000 +16%
MG
58
Marex Group
$3.67M +$3.69M +262,000 New
Swiss National Bank
59
Swiss National Bank
Switzerland
$3.51M
PAI
60
Palo Alto Investors
California
$3.35M +$3.38M +239,809 New
Invesco
61
Invesco
Georgia
$3.07M +$427K +30,368 +16%
RhumbLine Advisers
62
RhumbLine Advisers
Massachusetts
$2.97M +$313K +22,247 +12%
TC
63
TwinBeech Capital
New York
$2.94M +$1.95M +138,348 +192%
EDRH
64
Edmond de Rothschild Holding
Switzerland
$2.88M
SCM
65
SCS Capital Management
Massachusetts
$2.77M
Renaissance Technologies
66
Renaissance Technologies
New York
$2.74M +$318K +22,600 +13%
JP Morgan Chase
67
JP Morgan Chase
New York
$2.68M +$45.2K +3,210 +2%
SCM
68
Soleus Capital Management
Connecticut
$2.55M +$663K +47,110 +35%
GAM
69
Groupama Asset Management
France
$2.47M +$437K +31,043 +21%
TRSOTSOK
70
Teachers Retirement System of the State of Kentucky
Kentucky
$2.4M -$167K -11,839 -6%
DCM
71
DAFNA Capital Management
California
$2.36M +$571K +40,600 +32%
Susquehanna International Group
72
Susquehanna International Group
Pennsylvania
$2.25M -$85.3K -6,061 -4%
CCIA
73
Campbell & Co Investment Adviser
Maryland
$2M +$1.05M +74,523 +109%
State of New Jersey Common Pension Fund D
74
State of New Jersey Common Pension Fund D
New Jersey
$1.93M +$623K +44,290 +47%
Deutsche Bank
75
Deutsche Bank
Germany
$1.9M -$285K -20,283 -13%

DNLI Hedge Fund Activity: Q2 2025 in Review

230 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2025, worth a combined $1.93B — up 4.1% from $1.85B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new DNLI positions and 36 closed out — a net gain of 9 holders — while 84 added to existing stakes and 64 trimmed.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $45.7M. The largest seller was Wellington Management Group, cutting an estimated $80.9M.

  • 230 institutional investors held Denali Therapeutics (DNLI) as of Q2 2025, up from 222 in Q1 2025.
  • Funds reported $1.93B of Denali Therapeutics stock for Q2 2025, up 4.1% quarter-over-quarter.
  • 45 funds opened new Denali Therapeutics positions in Q2 2025 and 36 closed out, a net change of +9 holders.
  • The largest Denali Therapeutics buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $45.7M added.
  • The largest Denali Therapeutics seller in Q2 2025 was Wellington Management Group, an estimated $80.9M sold.

Based on aggregated 13F filings for Q2 2025.